|
Parameter
|
n
|
%
|
|---|
|
World Health Organization diagnosis
| | |
|
Invasive ductal
|
230
|
86
|
|
Invasive lobular
|
32
|
12
|
|
Ductal with ductal carcinoma in situ
|
2
|
1
|
|
Unknown
|
4
|
1
|
|
Total
|
268
| |
|
Tumor grade
| | |
|
1
|
62
|
27
|
|
2
|
103
|
45
|
|
3
|
63
|
28
|
|
Total
|
228
| |
|
Tumor size
| | |
|
<2 cm
|
85
|
32
|
|
2 to 5 cm
|
161
|
60
|
|
>5 cm
|
22
|
8
|
|
Total
|
268
| |
|
Nodal status
| | |
|
0
|
22
|
8
|
|
1 to 3
|
149
|
56
|
|
≥4
|
97
|
36
|
|
Total
|
268
| |
|
Receptor status (estrogen receptor or progesterone receptor)
| | |
|
Negative
|
1
|
0
|
|
Positive
|
267
|
100
|
|
Total
|
268
| |
|
HER2
| | |
|
Negative
|
246
|
92
|
|
Positive
|
22
|
8
|
|
Total
|
268
| |
|
Recurrence
| | |
|
No
|
179
|
67
|
|
Yes
|
89
|
33
|
|
Total
|
268
| |
|
Death
| | |
|
No
|
146
|
54
|
|
Yes
|
122
|
46
|
|
Total
|
268
| |
- Tumor grade was scored according to Bloom and Richardson. HER2 was analyzed by standard testing (that is, the HercepTest™), followed by fluorescence in situ hybridization analysis of the cases scoring 2+.
